Gland Pharma Stock - Analyst consensus and valuation snapshot

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/22/2026, 12:20 UTC. Details in the imprint.

Gland Pharma (INE068V01023) remains a mid-cap name in India's pharma universe with limited fresh corporate headlines today. Instead, investors are watching how current analyst estimates and valuation metrics stack up against peers in the injectables and contract manufacturing space.

What the estimates show

On quiet news days like today, the focus shifts to how Gland Pharma is valued against its current earnings power and growth outlook. According to Indian brokerage data aggregators, the stock trades around the low- to mid-50s on a trailing price-earnings multiple based on recent prices near INR 2,199.

At this level, the company sits at a premium to some broader Indian pharma names but broadly in line with niche injectable and contract development specialists. Market data from several platforms put Gland Pharma's market capitalization in the mid-INR 30,000 crore range based on recent pricing and shares outstanding.

Analyst coverage and consensus

Sell-side coverage on Gland Pharma centers on three themes: integration of past acquisitions, US pricing pressures and capacity utilization across key production sites. Brokerage research referenced in Indian market summaries indicates a mixed but cautiously constructive stance, with a blend of Buy, Hold and fewer explicit Sell ratings.

Consensus commentary points out that the stock has recovered meaningfully from its mid-2023 lows after earlier margin pressure and a profit warning, but that performance in the last few months has been more range-bound as investors monitor execution and US demand trends.

The product behind the stock

Gland Pharma generates revenue mainly from generic sterile injectables, contract development and manufacturing services and oncology formulations. The company supplies hospital and clinic customers in India and export markets, including the United States, where regulatory compliance and product reliability are critical to its positioning.

Where the stock trades today

Gland Pharma shares trade on the National Stock Exchange of India and BSE at around INR 2,199 as of the most recent available quote on 06/22/2026 during Monday trading hours.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.